214 related articles for article (PubMed ID: 33765337)
1. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
Harrison MR; Costello BA; Bhavsar NA; Vaishampayan U; Pal SK; Zakharia Y; Jim HSL; Fishman MN; Molina AM; Kyriakopoulos CE; Tsao CK; Appleman LJ; Gartrell BA; Hussain A; Stadler WM; Agarwal N; Pachynski RK; Hutson TE; Hammers HJ; Ryan CW; Inman BA; Mardekian J; Borham A; George DJ
Cancer; 2021 Jul; 127(13):2204-2212. PubMed ID: 33765337
[TBL] [Abstract][Full Text] [Related]
2. Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre.
Stares M; Chauhan V; Moudgil-Joshi J; Kong QG; Malik J; Sundaramurthy A; Elliott T; Mains E; Leung S; Laird A; Symeonides SN
Cancer Med; 2023 Mar; 12(5):5255-5264. PubMed ID: 36207803
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers.
Dragomir A; Nazha S; Tanguay S; Breau RH; Bhindi B; Rendon RA; Kapoor A; Hotte SJ; Basappa N; Fairey A; So AI; Kollmannsberger C; Finelli A; Hansen A; Canil C; Heng D; Lattouf JB; Bjarnason G; Power N; Pouliot F; Wood LA
Eur Urol Focus; 2022 Nov; 8(6):1703-1710. PubMed ID: 34736870
[TBL] [Abstract][Full Text] [Related]
4. Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases.
Parmar A; Soliman H; Sahgal A; Bjarnason GA
Clin Genitourin Cancer; 2020 Jun; 18(3):e224-e232. PubMed ID: 32139300
[TBL] [Abstract][Full Text] [Related]
5. Deferred systemic therapy in patients with metastatic renal cell carcinoma.
Mitchell AP; Hirsch BR; Harrison MR; Abernethy AP; George DJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e159-66. PubMed ID: 25770767
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma.
Parmar A; Ghosh S; Sahgal A; Lalani AA; Hansen AR; Reaume MN; Wood L; Basappa NS; Heng DYC; Graham J; Kollmannsberger C; Soulières D; Breau RH; Tanguay S; Kapoor A; Pouliot F; Bjarnason GA
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1763. PubMed ID: 36517084
[TBL] [Abstract][Full Text] [Related]
7. Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System.
Kushnir I; Basappa NS; Ghosh S; Lalani AA; Hansen AR; Wood L; Kollmannsberger CK; Heng DYC; Bjarnason GA; Soulières D; Dawe DE; Tanguay S; Breau RH; Pouliot F; Kapoor A; Graham J; Reaume MN
Clin Genitourin Cancer; 2021 Dec; 19(6):521-530. PubMed ID: 34158246
[TBL] [Abstract][Full Text] [Related]
8. Patterns of care for metastatic renal cell carcinoma in Australia.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Andrews M; Davis ID; Azad AA; Rosenthal M; Wong S; Johnstone A; Gibbs P; Tran B
BJU Int; 2015 Oct; 116 Suppl 3():36-41. PubMed ID: 26204961
[TBL] [Abstract][Full Text] [Related]
9. Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.
Mytsyk Y; Pasichnyk S; Dutka I; Dats I; Vorobets D; Skrzypczyk M; Uteuliyev Y; Botikova A; Gazdikova K; Kubatka P; Urdzik P; Kruzliak P
Clin Exp Med; 2020 May; 20(2):277-287. PubMed ID: 32026157
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
11. Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.
Bhavsar NA; Harrison MR; Hirsch BR; Creel P; Wolf SP; Samsa GP; Abernethy AP; Simantov R; Borham A; George DJ
Cancer Invest; 2017 May; 35(5):333-344. PubMed ID: 28368708
[TBL] [Abstract][Full Text] [Related]
12. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
Hawkins R; Fife K; Hurst M; Wang M; Naicker N; Nolasco S; Eisen T; Matakidou A; Gordon J
BMC Cancer; 2020 Jul; 20(1):670. PubMed ID: 32680483
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
[TBL] [Abstract][Full Text] [Related]
15. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry.
Tsimafeyeu I; Zolotareva T; Varlamov S; Zukov R; Petkau V; Mazhbich M; Statsenko G; Safina S; Zaitsev I; Sakaeva D; Popov A; Borisov P; Vladimirova L
Clin Genitourin Cancer; 2017 Dec; 15(6):e1069-e1072. PubMed ID: 28882737
[TBL] [Abstract][Full Text] [Related]
16. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma.
Navani V; Ernst M; Wells JC; Yuasa T; Takemura K; Donskov F; Basappa NS; Schmidt A; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; Powles T; McKay RR; Weickhardt A; Suarez C; Kapoor A; Lee JL; Choueiri TK; Heng DYC
JAMA Netw Open; 2022 Jun; 5(6):e2216379. PubMed ID: 35687336
[TBL] [Abstract][Full Text] [Related]
17. First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
Matsubara N; Mukai H; Naito Y; Itoh K; Komai Y; Sakai Y
Urology; 2013 Jul; 82(1):118-23. PubMed ID: 23806397
[TBL] [Abstract][Full Text] [Related]
18. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
20. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.
Joshi SS; Handorf EA; Zibelman M; Plimack ER; Uzzo RG; Kutikov A; Smaldone MC; Geynisman DM
Eur Urol; 2018 Sep; 74(3):387-393. PubMed ID: 29880274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]